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Abstract
Calcitonin gene-related peptide (CGRP) was found to stimu-
late renin secretion in vivo in normal human volunteers. More-
over, CGRP stimulated the release of renin in vitro from iso-
lated rat renal juxtaglomerular cells (half-maximal effective
concentration IECsoI 100 nM) concomitant with stimulation of
cAMP production (EC5" 60 nM). Immunoreactive CGRP was
recognized in rat renal cortical nerve fibers, and intact rat
CGRP was identified in extracts of the rat renal cortex. Be-
cause CGRP containing sensory nerve fibers are seen in the
region ofthe juxtaglomerular apparatus, it would seem that the
release of CGRP from these afferent nerves may be involved in
the physiological control of renin secretion.
Introduction
Calcitonin gene-related peptide (CGRP)' (1) is a 37-amino
acid polypeptide that results from the tissue-specific processing
of the primary RNA transcript of the calcitonin gene (1-4).
CGRP was identified in the central nervous system (CNS), but
also in thyroid C cells (2, 3, 5). As a neuropeptide, CGRP is
considered to act as neurotransmitter or neuromodulator in
the CNS and peripheral nervous system (6, 7). The physiologi-
cal roles ofCGRP remain to be clarified. Recent observations
are consistent with a function ofCGRP in cardiovascular regu-
lation. CGRP thus causes relaxation of small arteries and has
positive chronotropic and inotropic effects on the hearts of
man and experimental animals (8-12).
Several vasoactive hormones affect the humoral control of
circulation by changing the release of renin from renal juxta-
glomerular cells. Vasoconstrictive hormones generally inhibit
renin secretion, whereas most vasodilating hormones stimu-
late release (13). So far, it remains to be demonstrated whether
CGRP, which is a potent vasodilator, also stimulates renin
secretion directly.
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In human tissues, CGRP has been identified in two forms,
I and II (or a and p3), which differ in three amino acids (3-5).
CGRP-I and -II were equally effective in stimulating the con-
tractility of isolated human auricles and causing relaxation of
small arteries (12). Here, we have examined the effects of
human CGRP-II on renal and cardiovascular functions in
humans. Moreover, CGRP has been localized in rat kidneys,
and rat CGRP was shown to stimulate renin secretion from
isolated rat renal juxtaglomerular cells.
The results obtained suggest that CGRP may be involved
in the physiological regulation ofrenin secretion by the periph-
eral nervous system.
Methods
Peptides. Synthetic human CGRP-II and rat CGRPa were purchased
from Peninsula Laboratories, Belmont, CA. Over 90% of synthetic
human CGRP-II and rat CGRPa eluted as single peaks on reverse-
phase HPLC (5). Human CGRP-II was dissolved in 0.15 M NaCi and
0.1% HSA, and vials containing 6.6 nmol/ml were prepared under
aseptic conditions by the University of Basel Hospital Pharmacy,
Basel, Switzerland, and stored at -200C. Synthetic human calcitonin
(Cibacalcin) was donated by Ciba-Geigy Ltd., Basel, Switzerland.
In vivo studies. 10 healthy male volunteers received intravenous
infusions of synthetic human CGRP-II at an initial rate of 1.2 pmol/kg
per min, followed by 4.2 pmol/kg per min for 60 min. For comparison,
synthetic human calcitonin (4.2 pmol/kg per min) was administered to
five of the subjects receiving CGRP. The study has been approved by
the Ethics Committee of the University of Bern Hospital, Bern, Swit-
zerland, and informed consent was obtained from each subject inves-
tigated. Plasma renin activity, effective renal plasma flow, glomerular
filtration fraction, arterial pressure, and heart rate were monitored
before, during, and after the infusions. 0.9% NaCI was infused at a rate
of 1 ml/min for 240 min. 1.2 pmol/kg per min was added between 60
and 120 min, and 4.2 pmol/kg per min CGRP-II was added between
120 and 180 min. Plasma renin activity and aldosterone concentra-
tions were measured by RIA (14). The arterial pressure was determined
by an automatic device (Tonoprint; Speidel and Keller, Jungingen,
FRG), and the heart rate by counting the radial pulse. Effective renal
plasma flow and the filtration fraction were analyzed using a constant
infusion technique of 5"Cr-EDTA and paraminohippuric acid in blad-
der-catheterized subjects. Statistical analysis was done with the SAS-
software package (statistical analysis system, version 50; SAS Institute,
Cary, NC) using an analysis of covariance and the t test.
Renin release from isolated juxtaglomerular (JEG) cells. Primary
cell cultures of rat JEG cells were prepared as single cell suspensions by
perifusion of rat kidneys with citrate, dissociation with trypsin and
collagenase, and sieving through a 22-,um screen as described ( 15, 16).
The cells were further separated on a 25% isoosmotic Percoll gradient,
and cells with a density of 1.06 g/ml were used for culture. On the
second day of culture, 90% of the attached cells were JEG-cells, as
judged from the specific immunostaining for rat renin (15). Determi-
nation of renin release from the cells was done by measuring the linear
increase of renin activity of the cell supernatant in the absence and
presence of rat CGRP and rat and salmon calcitonin, at 10, 20, and 30
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min after the start of the experiments. The culture medium was re-
placed with prewarmed Hepes-buffered solution (132 mM NaCl, 5
mM KCl, 0.8 mM MgSO4, 2 mM CaC12, 10 mM sodium acetate, 2
mM NaH2PO4, 10 mM glucose, and 20 mM Hepes, pH 7.2). The
culture dishes were then placed on a heating block at 37°C, and the
time-dependent increase of renin activity of the buffer was monitored.
Renin activity was determined by its ability to generate angiotensin I
from the plasma of bilaterally nephrectomized rats as described (16).
At the end of the experiments, the cells were lysed by the addition of 1
N NaOH and cellular protein was determined according to the method
of Lowry (17).
cAMP measurements. For determination of the cellular cAMP
content, the culture medium was replaced with the buffer used for the
measurement of renin release, and the culture dishes were placed on a
heating block at 370C. At the end of the incubations, the buffer was
withdrawn and the dishes were placed on an ice block. Then, 0.4 ml
ice-cold buffer containing 5 mM potassium phosphate, 2 mM EDTA,
0.5 mM 3-isobutyl- l-methyl-xanthine (IBMX), and 150 mM KCl (pH
6.8) were added, and the cells were scraped with a Teflon policeman.
The cells were sonicated and boiled for 5 min and centrifuged. The
supernatants were assayed for cAMP using a specific binding assay
(18). The pellets were lysed with 1 N NaOH and used for protein
determination (17).
Immunohistochemistry. 50 mg/kg capsaicin was administered 1 wk
before killing and control rats (150-200 g body wt; ALAB, Stockholm,
Sweden) received the vehicle alone. The rats were anesthetized with
sodium pentobarbital (50 mg/kg Nembutal), and perfused via the as-
cending aorta with Tyrode's solution, followed by picric acid contain-
ing formalin, and further processed as described (19). Immunofluores-
cence staining of rat renal cryosections was done as described in detail
elsewhere (19). Antiserum to rat CGRPa was purchased from Penin-
sula Laboratories.
Extraction ofCGRP. Pools of 10 rat kidneys obtained immediately
after decapitation were used with the pelvis removed. The rest of the
kidneys was minced and placed in 10 vol of 2 M acetic acid, and
transferred to a boiling water bath for 5 min. Subsequently, the tissues
were homogenized for 5 min using an Ultra-Turrax homogenizer
(IKA-Werk; Staufen, FRG), and the homogenates were centrifuged at
48,000 g for 30 min at 4°C. Clear supernatants were adsorbed to
octadecasilyl silica Sep-Pak C18 cartridges (Waters Associates, Milli-
pore Corp., Milford, MA), and eluted with 60% (vol/vol) acetonitrile
containing 0.1% trifluoroacetic acid as described (20). Lyophilized
eluates were dissolved in solvent containing 20% acetonitrile and sub-
jected to reverse phase HPLC with Nucleosil C18 using a linear gra-
dient of acetonitrile (20-58%). Effluent fractions were analyzed for
immunoreactive CGRP (21) and calcitonin (22). The recovery ranged
from 60 to 80%.
Results
Human CGRP-II was intravenously infused in healthy human
volunteers, and the results are summarized in Table I. Infusion
of 4.2 pmol CGRP-II/kg per min caused an increase of the
plasma renin activity (P < 0.05). The filtration fraction and the
heart rate were also raised, whereas the diastolic arterial pres-
sure and the effective renal plasma flow were lowered (P
< 0.05). Plasma aldosterone levels were not consistently
changed.
For comparison, we have also examined the effect of syn-
thetic human calcitonin (4.2 pmol/kg per min) in 5 out of the
10 volunteers. Calcitonin at this dose did not alter the heart
rate, arterial pressure, renal plasma flow, filtration fraction,
and plasma aldosterone concentrations. A small increase of
17±15% (mean±SEM; n = 5) in plasma renin activity was
statistically not significant (P > 0.1).
A possible direct effect of rat CGRP on renin secretion was
analyzed in isolated rat renal JEG cells (Fig. 1). There, rat
CGRP caused a threefold stimulation of renin secretion (half-
maximal effective concentration [EC50] 100 nM). In the rat
hypocalcemia assay, rat calcitonin is less potent than salmon
calcitonin. Along the same lines, rat calcitonin did not stimu-
late renin secretion, whereas salmon calcitonin was still much
less effective than rat CGRPa in raising renin secretion. The
stimulation of renin secretion by CGRP was paralleled by a
transient increase (EC5o 80 nM) of cellular cAMP levels (Fig.
2). The effect of CGRP on cAMP was enhanced in the pres-
ence of the phosphodiesterase inhibitor IBMX. The EC50 for
cAMP production by CGRP (60 nM) and for the stimulation
of renin secretion (100 nM) were similar. Stimulation of
cAMP formation by CGRPa was not mediated by f3-adrenore-
ceptors because the presence ofthe ,3-receptor antagonist, pro-
pranolol (0.1 ,uM), did not affect CGRP (0.01 and 0.1 tM)
stimulated cAMP formation.
To reveal possible sources of endogeneously released
CGRP, kidney sections were processed for CGRP immunoflu-
orescence histochemistry (Fig. 3). CGRP-immunoreactive
Table I. Effects ofIntravenous Infusion ofHuman CGRP-II in Normal Human Volunteers (n = 10) on Plasma Renin Activity,
Systolic and Diastolic Arterial Pressure, Heart Rate, Effective Renal Plasma Flow, and Filtration Fraction
Infusion Control CGRP CGRP Recovery
1.2 pmol/kg per min 4.2 pmol/kg per min
Time (min) 50 110 170 230
BPy,, (mmHg) 113±3 111±3 109±3 112±3
BPdias (mmHg) 59±2 54±3 45±3* 55±3
HR (min-') 57±3 62±3 78±4* 62±2
eRPF (ml/min) 533±26 453±18 422±22t 516±42
FF (%) 21.1±0.8 21.7±1.1 24.0±1.2* 21.2±0.9
PRA (ng/ml per h) 1.45±0.08 1.36±0.09 1.98±0.28t 1.34±0.11
Aldosterone (pg/ml) 78.7±8.2 54.5±3.4 67.1±9.5 53.3±4.6
0.9% NaCl was infused at a rate of 1 ml/min for 240 min. 1.2 pmol/kg per min CGRP-II was added between 60 and 120 min, and 4.2 pmol/kg
per min CGRP-II between 120 and 180 min. Values are means±SEM. * P < 0.01 vs control period; * P < 0.05. Abbreviations: BP, systolic
and diastolic arterial pressure; eRPF, effective renal plasma flow; FF, filtration fraction; HR, heart rate; PRA, plasma renin activity.
Calcitonin Gene-related Peptide Stimulates Renin Secretion 539
IF
1-
. 10-8 10-7
Concentration (M)
10-6
Figure 1. Effects of rat CGRPa and of rat and salmon calcitonin on
the release of renin from isolated rat renal JEG epitheloid cells.
Values are means±SEM (n = 10 independent experiments). *P
< 0.05 vs. control values. *, rat CGRP; *, rat calcitonin; o, salmon
calcitonin.
nerve fibers were visualized throughout the kidney. The den-
sest innervation was seen within the smooth muscle layer in
the pelvis and close to the epithelium (Fig. 3 A). Many small
arteries and arterioles received a prominent innervation (Fig. 3
B). Some fibers could be followed into the parenchyma sur-
rounding tubules without any apparent association with blood
vessels (Fig. 3 C). Thin and smooth varicose fibers were also
seen close to the glomeruli with associated arterioles and JEG
cells (Figs. 3 E and F). A marked decrease in the number of
CGRP-immunoreactive nerve fibers around blood vessels was
observed after treatment with capsaicin (Fig. 3 D). Immuno-
fluorescence was obliterated by exposure of the sections to 1
,gM rat CGRPa, but not to 1 ,uM rat calcitonin.
Intact CGRP was, moreover, identified in extracts of the
rat kidney cortex (Fig. 4). Immunoreactive CGRP had the
retention time on HPLC of synthetic rat CGRPa, whereas rat
calcitonin was not detected.
Discussion
Here we have investigated the effects ofCGRP on renin secre-
tion. To this end, administration of CGRP-II to normal
human volunteers caused a rise of plasma renin activity that
indicates stimulation of renal renin secretion (Table I). An
observed fall in renal plasma flow and a rise in filtration frac-
tion are consistent with efferent arteriolar vasoconstriction,
which may result from activation of the intrarenal renin-an-
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Figure 2. Effects of rat CGRPa on cellular cAMP levels in isolated
rat JEG cells. cAMP content was measured as a function of the incu-
bation time period in the absence of IBMX (A), and in the absence
and presence of 0.5 mM IBMX after incubation for 10 min (B).
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Values are means±SEM (n = 6 experiments). *P < 0.05 vs. control.
In A, CGRP, in moles per liter: o, 0; ., 10-8; A, 10-7; , 10-6. In B, o,
without IBMX; *, with 0.5 mM IBMX.
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Figure 4. Reverse phase HPLC profile of immunoreactive CGRP (o)
and calcitonin (&) extracted from rat kidneys. The sulfoxide form of
[13H]substance P (A), [3H]substance P (B), and [3H]salmon calcitonin
(C) were included as calibration markers. Arrows, retention times of
synthetic rat CGRPa (rCGRP) and rat calcitonin (rCT) analyzed
separately. o, CGRP; A, CT pmol/g tissue. - - -, %CH3CN.
giotensin system (23). The decrease in diastolic arterial pres-
sure most likely reflects a fall of peripheral vascular resistance
due to CGRP (8-12).
To test whether CGRP stimulates renin secretion in vivo
indirectly as a result of the fall in arterial pressure (24), or by
direct stimulation of renin-secreting cells, we have examined
the effect of rat CGRP on isolated JEG cells. Here, CGRP
caused a threefold stimulation of renin secretion, which indi-
cates that CGRP may have a direct regulatory influence on
JEG cells (Fig. 1).
In view of the structural homology between CGRP and
calcitonin and the cross-tachyphylaxis observed between the
two peptides (25-27), we have also investigated possible effects
of rat and salmon calcitonin on renin secretion in vitro and in
vivo. On a molar basis, CGRP was more active in stimulating
renin secretion than salmon calcitonin, and rat calcitonin was
inactive (Fig. 1). Our results thus confirm the recent observa-
tion that salmon calcitonin stimulates renin secretion in
humans (28). Also in vivo, human calcitonin in equimolar
amounts in relation to CGRP did not affect plasma renin
activity. The findings suggest that CGRP, rather than calci-
tonin, interacts with receptors on JEG cells. The numerical
similarity ofEC50 values for cAMP production (Fig. 2) and the
release of renin (Fig. 1) are consistent with a linkage between
activation of adenylate cyclase by CGRP and renin secretion
(26, 27, 29, 30).
cAMP is so far the best characterized mediator of renin
secretion in JEG cells (31) and CGRP apparently stimulates
the release of renin from the cells by activation of adenylate
cyclase. The EC50 values of CGRP for renin secretion and
adenylate cyclase activation are similar to those for the stimu-
lation of the heart rate and the contractility of the rat atrium
(26). However, the ECQ0 values were much higher than circu-
lating levels of the peptide that have been reported to range
from < 10 to 100 pM in normal human subjects (32, 33). The
juxtaglomerular cells in situ may be exposed to higher local
concentrations of CGRP released from nerves, much like in
the heart and in blood vessels. In fact, we have identified
CGRP, but not calcitonin in the renal cortex (Fig. 4).
Renin is synthesized, stored, and released from the JEG
cells, which are localized in the wall of afferent arterioles just
adjacent to the glomeruli. Using immunohistochemistry,
CGRP-like immunoreactivity was localized in several regions
ofthe kidney, including fibers in proximity ofthe juxtaglomer-
ular apparatus. The presence of these fibers suggests that neu-
ronally released CGRP acts directly on renin-secreting cells.
From the observation that the CGRP immunoreactivity was
decreased after capsaicin treatment, it may be inferred that
immunoreactive nerves were of sensory origin (19).
Together, our findings provide strong evidence that CGRP
is present in renal sensory nerve fibers near arterioles close to
glomeruli. This may imply that CGRP is locally released and
as a result increases the secretion of renin from the juxtaglo-
merular apparatus. CGRP may be involved in the physiologi-
cal regulation of renin secretion by the peripheral nervous
system. Physiological mechanisms controlling the release of
CGRP from nerve fibers and the physiological relevance ofthe
effect ofCGRP on renal JEG cells remain to be clarified.
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